<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="104259">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01985061</url>
  </required_header>
  <id_info>
    <org_study_id>AAA-IPC2011-003</org_study_id>
    <nct_id>NCT01985061</nct_id>
  </id_info>
  <brief_title>Evaluation of 3 Different Doses of IV Busulfan</brief_title>
  <acronym>AAA</acronym>
  <official_title>Prospective and Multicentre Evaluation of 3 Different Doses of IV Busulfan Associated With Fludarabine and Thymoglobuline in the Conditioning of Allogeneic Stem Cell Transplantation (SCT) From a Matched Related or Unrelated Donor in Patients With Poor Prognosis Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Paoli-Calmettes</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Albeit the safety of the stem cell transplantation procedure has been greatly improved,
      further refining the intensity of the conditioning is an important issue to explore,
      especially in patients with poor prognosis, the goal being to maintain the very favorable
      safety profile and improve the disease control. This is the goal our prospective trial; we
      aim to prospectively evaluate in a prospective multicenter trial the efficacy of different
      conditioning regimens in patients with high-risk myeloid malignancies.

      The study is a phase II trial randomizing patients between a prospective active control arm
      (BX2) and two experimental arms (BX3 and BX4). A standard group was kept in this clinical
      trial in order to avoid the limitations induced by the comparison with historical controls
      in the context of continuously improving practice. Each experimental arm will be conducted
      in parallel according to a standard phase II trial design.

      In addition, this trial will associate four ancillary studies to the main clinical
      objective: 1/ a prospective assessment of the quality of life of the patients over a period
      of 2 years 2/ an analysis of the cost effectiveness of the procedure, assessed over a period
      of 2 years 3/ an observational busulfan pharmacokinetic study 4/ a busulfan pharmacogenomic
      study
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Time to progression or death</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>2-year progression free survival rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to neutrophil&gt;0.5G/l and platelets&gt;50G/l</measure>
    <time_frame>up to 2 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>hematologic recovery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft versus host disease</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse</measure>
    <time_frame>up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of grade 3-4 adverse events according the CTC-AE v4.0 scale</measure>
    <time_frame>up to 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>safety</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>BX2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine (Fludara®): 30 mg/m2 on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-4 and D-3 Thymoglobuline®: 2.5 mg/kg/d on D-3 and D-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BX3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine (Fludara®): 30 mg/m² on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BX4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fludarabine (Fludara®): 30 mg/m²on D-6, D-5, D-4, D-3 and D-2 Busulfan IV (Busilvex®) : 3.2 mg/kg/d on D-6, D-5, D-4 and D-3 Thymoglobuline® : 2.5 mg/kg/d on D-3 and D-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BX2</intervention_name>
    <arm_group_label>BX2</arm_group_label>
    <other_name>Busulfan Intravenous 2 days at 3.2 mg/kg/d</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BX3</intervention_name>
    <arm_group_label>BX3</arm_group_label>
    <other_name>Busulfan Intravenous 3 days</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BX4</intervention_name>
    <arm_group_label>BX4</arm_group_label>
    <other_name>Busulfan intravenous 4 days</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with poor prognosis myeloid malignancies:

               -  Myelodysplastic syndrome,

               -  Acute Myeloid Leukemia (AML) beyond Complete Response (CR1),

               -  CR1 AML with poor risk cytogenetics

          2. Adult patients: aged ≥ 55 years up to 65 or &lt; 55 years not eligible for myeloablative
             conditioning regimen based on Total Body Irradiation (TBI) or double alkylating agent
             combinations.

          3. Availability of a HLA identical sibling or matched unrelated donor (10/10)

          4. Affiliation to social security

          5. Written Informed Consent

        Exclusion Criteria:

          1. History of previous Allo-Hematological Stem Cell Transplantation (HSCT)

          2. HIV positivity

          3. Signs of chronic active hepatitis B and/or C

          4. Evolutive psychiatric disease

          5. Concomitant neoplastic disease

          6. Pregnant or lactating woman or without contraception (for child bearing potential
             wom-en)

          7. Usual contra-indications for Allo-HSCT
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Didier BLAISE, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Paoli-Calmettes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominique GENRE, MD</last_name>
    <phone>33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Agnès BOYER CHAMMARD, MD</last_name>
    <phone>33491223778</phone>
    <email>drci.up@ipc.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Agnès BOYER CHAMMARD, MD</last_name>
      <phone>33491223778</phone>
      <email>drci.up@ipc.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Didier BLAISE, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.institutpaolicalmettes.fr</url>
    <description>official web site of the sponsor</description>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 31, 2013</lastchanged_date>
  <firstreceived_date>October 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplasic syndrome</keyword>
  <keyword>Acute Myeloid leukemia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
